摘要
目的总结上颌窦腺样囊性癌的临床特征和治疗方法，探讨影响上颌窦腺样囊性癌患者预后的因素。方法回顾性分析中山大学肿瘤防治中心头颈外科1984年1月—2002年1月36例原发于上颌窦的腺样囊性癌患者的临床病理资料，回顾性分析单纯手术、单纯放疗与放疗结合手术等治疗方式的疗效。对其治疗与预后进行统计分析。生存分析采用Kaplan-Meier法，组间比较采用Log—Rank检验，多因素分析采用Cox比例风险模型。结果初次治疗结束后，全组有19例（19／36，52．8％）带瘤生存。全组患者的5年生存率为58、3％，其中Ⅲ期患者为75．0％，Ⅳ期患者为42．9％。手术＋放疗组、单纯手术组及单纯放疗组的5年生存率分别为66．7％、71．4％和12．5％。肿瘤分期、治疗方式和初次治疗后是否有肿瘤残留是影响上颌窦腺样囊性癌患者预后的独立因素（P值分别为0．047、0．035和0．024）。结论上颌窦腺样囊性癌的治疗以综合治疗为主，初次治疗后是否有肿瘤残留以及临床分期和治疗方法对预后有重要影响。
Objective To study the clinical characters, management and the prognosis of patients with adenoid cystic carcinoma of the maxillary sinus. Methods The clinical data were analyzed retrospectively for 36 patients with adenoid cystic carcinoma of the maxillary sinus to evaluate the treatment results of different modalities. The contribution of every factors influencing on survival were also analyzed. Survival analysis was performed by life table method, comparison among/between groups was performed using log-rank test, and multivariate analysis was carried out using Cox proportional hazard model. Results The 5-year survival rate was 58.33% in all patients, while they were only 75.0% and 42.9% in stage Ⅲ and stage Ⅳ lesions respectively. The 5-year survival rate of 66.7% was obtained in patients who received surgery combined with radiotherapy,71.4% and 12. 5% respectively in those treated by surgery and by radiotherapy alone. Multivariate analysis indicated that stage, treatment modality, and the tumour residues in the primary treatment were the predict factors for the prognosis. Conclusions Advanced adenoid cystic carcinoma should be treated by combined surgery and radiotherapy. Stage, treatment approach and shortterm therapeutic response are the most important factors affecting the prognosis of the patients with adenoid cystic carcinoma of the maxillary sinus.
出处
《中华耳鼻咽喉头颈外科杂志》
CAS
CSCD
北大核心
2008年第1期37-40,共4页
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
关键词
上颌窦肿瘤
癌
腺样囊性
存活率分析
预后
Maxillary sinus neoplasms
Carcinoma, adenoid cystic
Survival analysis
Prognosis
作者简介
通讯作者：杨安奎，Email：liuruntian_513@163．com
